吸烟者的间质性肺异常、肺气肿与肺量计检查
本研究基于COPDGene研究第1期(2007-2011年,9579人)和第2期(2012-2016年,5277人)的吸烟者数据,评估间质性肺异常(ILA,按Fleischner学会指南定义)与肺气肿对肺量计指标和肺功能的关联及交互作用。结果显示,第1期ILA患病率为6%(528例),第2期为11%(580例);ILA显著修饰肺气肿与FVC的关联(交互作用P<.0001)。第1期无ILA者肺气肿增加5%与FVC降低110 mL相关(95%CI -121至-100 mL,P<.0001),而有ILA者无此关联(-11 mL,95%CI -53至31,P=.59)。ILA与肺气肿对总肺容量或一氧化碳弥散量无交互作用。结论提示ILA减弱肺气肿相关的FVC下降。
要点
- 在吸烟者中,ILA显著修饰肺气肿与FVC的关联(交互作用P<.0001),第1期和第2期均如此。
- 第1期无ILA者,肺气肿每增加5%与FVC降低110 mL相关(95%CI -121至-100 mL,P<.0001)。
- 第1期有ILA者,肺气肿增加5%与FVC无显著关联(-11 mL,95%CI -53至31,P=.59)。
- ILA与肺气肿对总肺容量或一氧化碳弥散量无交互作用。
- COPDGene第1期ILA患病率6%(528/9579),第2期11%(580/5277)。
适用人群与场景
- COPDGene研究第1期(2007-2011年)和第2期的吸烟者,分别有9579和5277名参与者具有ILA和肺气肿的测量数据。
诊断标准与关键阈值
- ILA按Fleischner学会指南定义。
研究设计与关键结果
- 研究类型为基于COPDGene研究的横断面分析,纳入第1期9579名和第2期5277名吸烟者。
- 第1期ILA患病率为6%(528例),第2期为11%(580例)。
- ILA修饰肺气肿与FVC的关联(交互作用P<.0001),在第1期和第2期均存在。
- 第1期无ILA者,肺气肿增加5%与FVC降低110 mL相关(95%CI -121至-100 mL,P<.0001);有ILA者,肺气肿增加5%与FVC无显著关联(-11 mL,95%CI -53至31,P=.59)。
- ILA与肺气肿对总肺容量或一氧化碳弥散量无交互作用。
证据类型、等级与局限
- 证据类型:基于COPDGene研究第1期和第2期数据的横断面分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ILA的存在减弱肺气肿相关的FVC下降,在解读吸烟者肺功能时应考虑合并ILA的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Most pulmonary conditions reduce FVC, but studies of patients with combined pulmonary fibrosis and emphysema demonstrate that reductions in FVC are less than expected when these two conditions coexist clinically.
RESEARCH QUESTION: Do interstitial lung abnormalities (ILAs), chest CT imaging findings that may suggest an early stage of pulmonary fibrosis in individuals with undiagnosed disease, affect the association between emphysema and FVC?
STUDY DESIGN AND METHODS: Measures of ILA and emphysema were available for 9,579 and 5,277 participants from phases 1 (2007-2011) and 2 (2012-2016) of the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study (COPDGene), respectively. ILA were defined by Fleischner Society guidelines. Adjusted linear regression models were used to assess the associations and interactions among ILA, emphysema, measures of spirometry, and lung function.
RESULTS: ILA were present in 528 (6%) and 580 (11%) of participants in phases 1 and 2 of COPDGene, respectively. ILA modified the association between emphysema and FVC (P < .0001 for interaction) in both phases. In phase 1, in those without ILA, a 5% increase in emphysema was associated with a reduction in FVC (-110 mL; 95% CI, -121 to -100 mL; P < .0001); however, in those with ILA, it was not (-11 mL; 95% CI, -53 to 31; P = .59). In contrast, no interaction was found between ILA and emphysema on total lung capacity or on diffusing capacity of carbon monoxide.
INTERPRETATION: The presence of ILA attenuates the reduction in FVC associated with emphysema.
参考来源
- Menon AA, Putman RK, Sanders JL, et al. Interstitial Lung Abnormalities, Emphysema, and Spirometry in Smokers. Chest. 2021. PMID: 34742688. doi:10.1016/j.chest.2021.10.034
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。